Grant: Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Dalhousie University
$174,680.00
High resolution immunometabolomics for the discovery and verification of biomarkers of CAR-T efficacy
FY 2021-22 · 2021-07-01
Summary
Chimeric antigen receptor T-cells (CAR-T) are used to treat a variety of cancer. However, unlike well-defined drugs such as chemicals and antibodies, CAR-T are complex, living therapies. Therefore, it is difficult to objectively assess the potency of CAR-T. The overall objective of this project is to determine immunometabolomic biomarkers that can be measured prior to infusion of CAR-T into patients in order to predict the treatment efficacy for each patient.
The metabolic profile of all cells is determined by both their genomic makeup as well as their interaction with the environment. Unlike genomic profiles, the metabolomic profile can react rapidly to changes in nutrients, additives and other products added during the production of CAR-T cells from a patient’s own T-cells. Immunometabolomics can be used to rapidly and quantitatively profile hundreds of metabolites. By deploying advanced immunometabolomic techniques to the analysis of CAR-T cells in the context of on-going pre-clinical and clinical trials, we aim to identify robust immunometabolomic biomarkers of CAR-T efficacy.
Department
Program
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Recipient
Location
Halifax|Halifax, Nova Scotia, Canada
Recipient Type
Academia
Business Number
886806561
Type
Grant
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2021-07-01 | 2021-22 | $174,680.00 |
| 1 | 2021-07-01 | 2021-22 | $174,680.00 |
| 2 | 2021-07-01 | 2021-22 | $174,680.00 |
As published
Additional Information
This agreement has been amended 2 time(s). The end date of this agreement has been modified by 365 days.
Additional Information (French)
Cet accord a été modifié 2 fois. La date de fin du présent accord a été changé de 365 jours.
Agreement End Date
2025-06-30
Agreement Number
974328
Agreement Start Date
2021-07-01
Agreement Title
High resolution immunometabolomics for the discovery and verification of biomarkers of CAR-T efficacy
Agreement Title (French)
Application de l’immunométabolomique haute résolution à la recherche et à la validation de biomarqueurs de l’efficacité des cellules CAR-T
Agreement Type
Grant
Agreement Value
$174,680.00
Amendment Date
2024-06-17
Amendment Number
2
Description
Chimeric antigen receptor T-cells (CAR-T) are used to treat a variety of cancer. However, unlike well-defined drugs such as chemicals and antibodies, CAR-T are complex, living therapies. Therefore, it is difficult to objectively assess the potency of CAR-T. The overall objective of this project is to determine immunometabolomic biomarkers that can be measured prior to infusion of CAR-T into patients in order to predict the treatment efficacy for each patient.
The metabolic profile of all cells is determined by both their genomic makeup as well as their interaction with the environment. Unlike genomic profiles, the metabolomic profile can react rapidly to changes in nutrients, additives and other products added during the production of CAR-T cells from a patient’s own T-cells. Immunometabolomics can be used to rapidly and quantitatively profile hundreds of metabolites. By deploying advanced immunometabolomic techniques to the analysis of CAR-T cells in the context of on-going pre-clinical and clinical trials, we aim to identify robust immunometabolomic biomarkers of CAR-T efficacy.
Description (French)
Application de l’immunométabolomique haute résolution à la recherche et à la validation de biomarqueurs de l’efficacité des cellules CAR-T
Expected Results
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Expected Results (French)
À court terme, les résultats prévus seront des collaborations renforcées entre l'industrie, le milieu universitaire et le gouvernement pour soutenir l'excellence en recherche. À moyen terme, les résultats attendus seront le développement de nouvelles technologies potentiellement perturbatrices avec des collaborateurs. À long terme, trouver des solutions collaboratives aux défis des politiques publiques et créer des systèmes d'innovation plus solides.
Federal Riding
Halifax
Federal Riding (French)
Halifax
Federal Riding Number
12006
NAICS Code
541710 - R&D in the physical, engineering and life sciences
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Name (French)
Programme de collaboration en science, en technologie et en innovation - Initiatives de collaboration en R-D
Program Purpose
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.
Program Purpose (French)
Collaborer à des programmes multipartites de recherche-développement dans le but de profiter de la synergie entre la recherche transformatrice à haut risque et à haut rendement et le potentiel de découvertes scientifiques et de percées technologiques révolutionnaires dans des secteurs d’intervention prioritaires.
Recipient Business Number
886806561
Recipient City
Halifax|Halifax
Recipient Country
CA
Recipient Legal Name
Dalhousie University
Recipient Postal Code
B3H 4R2
Recipient Province or Territory
NS
Recipient Type
S
Reference Number
172-2021-2022-Q1-974328
